(0.32%) 5 116.47 points
(0.32%) 38 361 points
(0.36%) 15 985 points
(-0.85%) $83.14
(5.93%) $2.04
(0.37%) $2 355.90
(0.47%) $27.67
(4.01%) $959.05
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $15.49
発行日: 15 2月 2024 @ 05:23
リターン: -2.78%
前回のシグナル: 2月 15 - 02:00
前回のシグナル:
リターン: 1.51 %
Live Chart Being Loaded With Signals
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role...
Stats | |
---|---|
本日の出来高 | 121 304 |
平均出来高 | 805 816 |
時価総額 | 1.20B |
EPS | $-0.460 ( 2024-03-19 ) |
次の収益日 | ( $-0.490 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.57 |
ATR14 | $0.0210 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Peng Katie | Buy | 35 767 | Stock Option (Right to Buy) |
2024-04-09 | Peng Katie | Buy | 26 825 | Common Stock |
2024-02-16 | Myles Edward H | Sell | 4 744 | Common Stock |
2024-02-16 | Qatanani Mo | Sell | 2 512 | Common Stock |
2024-02-16 | Parlavecchio Caryn | Sell | 3 751 | Common Stock |
INSIDER POWER |
---|
57.33 |
Last 96 transactions |
Buy: 9 442 259 | Sell: 2 434 527 |
ボリューム 相関
Scholar Rock Holding Corp 相関
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Scholar Rock Holding Corp 相関 - 通貨/商品
Scholar Rock Holding Corp 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-2.84M (0.00 %) |
EPS: | $-1.990 |
FY | 2023 |
収益: | $0 |
総利益: | $-2.84M (0.00 %) |
EPS: | $-1.990 |
FY | 2022 |
収益: | $33.19M |
総利益: | $23.31M (70.22 %) |
EPS: | $-2.21 |
FY | 2021 |
収益: | $18.82M |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.59 |
Financial Reports:
No articles found.
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。